Nicholas Jacobus

Boehringer Ingelheim partners with Re-Vana Therapeutics to innovate long-acting eye disease treatments, enhancing patient care and compliance.

Hengrui Pharma partners with GSK to develop 12 innovative medicines, enhancing COPD treatment and expanding global growth opportunities.

The segment will provide education and support strategies.

Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene editing treatments for high-risk patients.

Congruence secures a $5 million grant to advance innovative therapies for GBA1 Parkinson's disease, enhancing hope for patients and research breakthroughs.

The acquisition led by Advent International will see the two AI-powered companies combine forces to improve the healthcare payment system.

Study presents overwhelming public support for providing aid to mothers in need.

The acquisition will bring Vicebo's Molecular Clamp technology under Sanofi's umbrella.

Regulators failed to halt production and importation of illegal GLP-1 compounds.

A special live broadcast of award-winning star and CEO’s conversation will focus on advancements and regulations on ALS sciences.

Amphix Bio leads breakthrough of regenerative spinal cord injury treatment.

The building will provide biotech startups necessary tools and space to conduct research and development.

Waterdrop’s advancements in AI technology earned the company a place in the collection.

Studies presented at the Society of Neurointerventional Surgery’s show links between GLP-1s and the prevention of strokes and reductions in brain injury complications.

The deep learning model increases handheld 3D medical imaging access.

The SVP of educational development’s contribution to the book displays SKNV’s approach to furthering education and professional development.

The direct-to-patient payment option is a resource for Eliquis patients to lower out-of-pocket costs and increase accessibility.

The reality TV star and certified obesity physician Dr. Holly Lofton plan to use the show to further educate GLP-1 users on potential side effects.

Alliance Pharmaceuticals plans to use the new to attack counterfeiters rather than just defend against them.

Leqselvi are currently available 8 mg tablets for severe Alopecia Areata treatments in adult patients.

LEO Pharma expected to expand Spevigo developments as well as improve access to care.

Bravecto Quantum becomes first FDA approved drug to protect dogs against fleas and ticks for 8 to 12 months.

rs6190 helps men build muscle mass and reduce diabetes risk, but increases cholesterol levels and elevates the risk of clogged arteries and heart disease in women.

The company will continue to experiment with microgravity-derived experiments.

TPN-101, a potent nucleoside reverse transcriptase inhibitor that specifically inhibits the LINE-1 reverse transcriptase.

The drug is currently in Phase 1 clinical trials for gastric cancer treatments.